<DOC>
	<DOCNO>NCT00532025</DOCNO>
	<brief_summary>This open-label , single-armed , multicentric , phase II study Sorafenib treatment follow surgery NSCLC . The primary hypothesis increase progression-free survival ( PFS ) experimental group comparison historical control group . For sample size calculation 2 year PFS 50 % calculated historical control group , 2 year PFS 67 % estimate intervention group . These estimate base actual PFS overall survival ( OS ) define population 120 NSCLC patient treat single institution surgery alone surgery follow adjuvant radiotherapy , compare favorably publish international result , improvement PFS achieve 4 cycle cisplatin/vinorelbine-based cytotoxic chemotherapy publish randomized trial .</brief_summary>
	<brief_title>Sorafenib Resected Non-small Cell Lung Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients histologically confirm diagnosis NSCLC pathological stage I , II III A Patients must completely resected disease may treat prior chemotherapy . Patients must fully recover surgery prior initiation study treatment . Adjuvant radiotherapy stage III A disease permit give patient recover radiationinduced toxicity . In patient , complete restaging perform prior enrolment trial . Patients completely resect NSCLC stage II III A , medical reason eligible adjuvant chemotherapy consist standard regimen 4 cycle cisplatin/vinorelbine Patients completely resect NSCLC stage II III A , willing undergo adjuvant chemotherapy 4 cycle cisplatin/ vinorelbine , also eligible . Age ≥ 18 year ECOG performance status ≤ 2 Normal organ marrow function define : Hematopoetic : absolute neutrophil count &gt; 1,500/mm3 , platelet count &gt; 100,000/mm3 , hemoglobin &gt; 9 g/dL INR &lt; 1.5 ULN PTT within normal limit Hepatic : total bilirubin &lt; 1.5 x ULN , AST ALT &lt; 2.5 x ULN Renal : creatinine &lt; 1.5 x ULN Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment Women childbearing potential men must agree use adequate birth contraception prior study entry duration study participation . Women men use adequate birth control least 3 month last administration Sorafenib . Written informed consent Any histology ( e.g . SCLC , carcinoid tumor ) disease stage I III A Patients eligible willing undergo standard adjuvant chemotherapy regimen ( 4 cycle cisplatin/vinorelbine ) Any prior systemic anticancer therapy include chemotherapy , target agent , experimental therapy biological therapy NSCLC Cardiac disease : congestive heart failure &gt; class II NYHA , patient must unstable angina pectoris new onset angina pectoris myocardial infarction within past 6 month , cardiac ventricular arrhythmia require antiarrhythmic therapy Uncontrolled hypertension define systolic blood pressure &gt; 150 mm Hg diastolic pressure &gt; 90 mm Hg , despite optimal therapy Known brain metastasis . Patients symptoms undergo CT scan/MRI brain exclude brain metastasis Active clinically serious infection &gt; NCICTCAE Grade 2 Thrombotic embolic event include transient ischemic attack within past 6 month Hemorrhage/bleeding event ≥ NCICTCAE Grade 3 within 4 week first dose study drug Serious nonhealing wound , ulcer bone fracture Evidence history bleed diathesis coagulopathy Therapeutic anticoagulation Vitamin K antagonists warfarin , phenprocoumon , heparins heparinoids . Low dose warfarin/phenprocoumon permit INR &lt; 1.5 . Low dose aspirin ( 300 mg/d ) permit . Use St John 's Wort rifampicin Major surgery , open biopsy significant traumatic injury within 4 week first dose study drug Known suspect allergy Sorafenib agent give course trial Previous cancer distinct primary site histology NSCLC except cervical cancer situ , treat basal cell carcinoma , superficial bladder tumor cancer curatively treat ≥ 3 year prior study entry . Substance abuse , medical psychological condition may interfere patient´s participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Adjuvant Treatment</keyword>
	<keyword>resect Non-Small Cell Lung Carcinoma</keyword>
</DOC>